In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin
1997
Drug Resistance in Small-Cell Lung Cancer
Sample size: 7
publication
Evidence: moderate
Author Information
Author(s): PB Jensen, B Holm, M Sorensen, IJ Christensen, M Sehested
Primary Institution: The Finsen Center, Rigshospitalet, Copenhagen, Denmark
Hypothesis
Can drug-resistant small-cell lung cancer cell lines be used to identify effective drug combinations?
Conclusion
The study found that certain drug combinations can overcome resistance in small-cell lung cancer cell lines.
Supporting Evidence
- Drug resistance was found to be highly drug specific.
- Patterns of collateral sensitivity were observed in multiple drug-resistant cell lines.
- Certain drug combinations showed promise in overcoming resistance.
Takeaway
Some cancer cells can resist treatment, but by mixing different drugs, we can find better ways to fight them.
Methodology
The study used a clonogenic assay to measure drug sensitivity in various resistant small-cell lung cancer cell lines.
Limitations
The findings may not directly translate to clinical settings due to the complexity of human tumors.
Want to read the original?
Access the complete publication on the publisher's website